Abamune L

Abamune-L is taken with other antiretroviral medications to treat adults infected with HIV-1. A single pill is the equivalent of 300 mg of Lamivudine IP and 600 mg of Abacavir. At least one other anti-HIV medication must be co-administered with Abamune L to effectively prevent HIV from progressing to AIDS. The recommended dose of Abamune-L for adults is one pill daily along with other antiretroviral medications. Abamune-L may be taken with or without food. Any patient who has hepatic impairment should not take Abamune-L. Anyone with a prior history of hypersensitive reaction to Abacavir or any of the other ingredients in Abamune L should also not take the drug. Do not take any Abacavir containing products after experiencing a hypersensitive reaction.  Taking Abamune-L has been associated with the following side effects: migraine, rash, nausea, fatigue, vomiting, diarrhea, gastritis, abnormal dreams, vertigo, headache, fever, anxiety, depression, insomnia. In rare incidences, cases of fatal hypersensitive reactions to Abacavir, a core ingredient of Abamune-L, have been reported. Other side effects may occur. Let a doctor know immediately if you feel any changes in your well being when you begin taking Abamune L. Abamune-L must not be co-administered with other medications containing Lamivudine or Abacavir. Patients who carry the HLA-B*5701 allele are at a heightened risk of hypertensive reaction to Abacavir. Because such reactions can be fatal, it is recommended that patients get tested for the allele even if they have tolerated other products containing Abacavir in the past. Abamune-L use must be suspended in symptoms of hepatotoxicity or lactic acidosis arise. Patients also taking interferon alfa should undergo regular monitoring for hepatic decomposition and toxicity. It is not safe to takeAbamune-L if you have a creatinine clearance of less than 50 ml/min. Ethanol may hinder the kidneys' ability to eliminate Abacavir. Zalcitabine cannot be coadministered with Abamune-L because Zalcitabine and Lamivudine inhibit one another. In trials with pregnant animals, use of Abamune-L has been associated with a higher risk of birth defects. Women who are pregnant can take Abamune-L only if the potential benefits mitigate the risks and there is no alternative. HIV positive mothers should not breastfeed because of the potential for postnatal transmission. The effects of an Abamune-L overdose are at this point unknown. Do not take more than the recommended dose.